慢性髓系白血病与结核病共病研究进展

Research progress of chronic myeloid leukemia complicated with tuberculosis

慢性髓系白血病是第一种发现与基因改变有关的血液恶性肿瘤,通过酪氨酸激酶抑制剂的靶向治疗可以获得功能性治愈。然而,当前仍有一些问题限制了它的治疗,合并结核病是其中一个重要因素。抗结核药物可通过改变肝酶代谢影响其他药物的药代动力学,并对慢性髓系白血病药物的靶向治疗构成挑战。未来仍然需要进一步的研究和专门的随机对照试验,以制定更为明确和充分的治疗指南,提高对慢性髓系白血病与结核病共病患者的治疗疗效。

Chronic myeloid leukemia is the first hematological malignancy found to be associated with genetic alterations.It can be functionally cured by targeted therapy with tyrosine kinase inhibitors.However,there are some problems that limit the treatment,and tuberculosis is one of the important factors.Anti-tuberculosis drugs can affect the pharmacokinetics of other drugs by altering the metabolism of liver enzymes and challenge the targeted treatment of chronic myeloid leukemia drugs.In the future,further research and special randomized controlled trials are still needed to formulate more clear and sufficient treatment guidelines,to improve the therapeutic efficacy of such patients.